SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process may be delayed.**

Drug Requested: (Select drug below)

❑ **Doptelet®** (avatrombopag)	❑ **Doptelet® Sprinkle** (avatrombopag)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosage and Quantity Limits:

Chronic liver disease and scheduled to undergo a procedure	Chronic immune thrombocytopenia
Platelet count 40,000 to <50,000/mm^3 Quantity Limit: 10 tablets Dosage: 2 tablets (40 mg) by mouth daily for 5 days	**Patients ≥ 6 years of age** Quantity Limit: 2 tablets per day Dosage: 20 mg once daily (Initial Dose Regimen); Maximum of 2 tablets (40 mg) once daily
Platelet count <40,000/mm^3 Quantity Limit: 15 tablets Dosage: 3 tablets (60 mg) by mouth daily for 5 days	**Patients ≥ 1 year to < 6 years of age** Quantity Limit: 2 capsules per day Dosage: 10 mg once daily (Initial Dose Regimen); Maximum of 2 capsules (20 mg) once daily

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ Diagnosis: Chronic Liver Disease-Associated Thrombocytopenia

ONE (1) TIME Service/Procedure-Date Approval

- ❑ Member has a diagnosis of chronic liver disease

AND

- ❑ Member is ≥ 18 years of age

AND

- ❑ Requested medication has been prescribed by or in consultation with a gastroenterologist or hematologist

AND

- ❑ Member is scheduled for an invasive procedure associated with moderate to high risk for bleeding

  [Moderate Risk: Liver biopsy, bronchoscopy, Ethanol ablation therapy or chemoembolization for hepatocellular carcinoma]

  [High Risk: Vascular catheterization (including right-side procedures in patients with pulmonary hypertension), Transjugular intrahepatic portosystemic shunt, Dental procedures, Renal biopsy, Biliary interventions, Nephrostomy tube placement, Radiofrequency ablation, Laparoscopic interventions]

  Name of procedure: _____ **Procedure date:** _____

  NOTE: Begin Doptelet 10-13 days prior to procedure (undergo procedure 5-8 days after the last dose)

AND

- ❑ Member has a baseline platelet count of ≤ 55 $x10^9/L$

  Document platelet count prior to therapy initiation: _____ $x10^9/L$

AND

- ❑ Select the corresponding dosing regimen for the member:
  - ❑ **Platelet count 40 $x10^9/L$ to <50 $x10^9/L$**
    Quantity Limit: 10 tablets
    Dosage: 2 tablets (40 mg) by mouth daily for 5 days
  - ❑ **Platelet count <40 $x10^9/L$**
    Quantity Limit: 15 tablets
    Dosage: 3 tablets (60 mg) by mouth daily for 5 days

(Continued on next page)

❑ Diagnosis: Chronic Immune Thrombocytopenia (ITP)

Initial Authorization: 6 months

- ❑ Member has a diagnosis of chronic ITP for at least 6 months (OR meets the corticosteroid requirement below)

AND

- ❑ Member is 1 year of age or older

AND

- ❑ Member's condition meets **ONE** of the following:
  - ❑ Documentation of platelet levels within the last 30 days has been submitted confirming < 30 x 10^9/L
  - ❑ Documentation of symptomatic bleeding, or high risk for bleeding, and platelet levels within the last 30 days has been submitted confirming < 50 x 10^9/L

AND

- ❑ Requested medication has been prescribed by or in consultation with a hematologist

AND

- ❑ Member must have failed a first-line therapy option with a corticosteroid at a recommended dose of 0.5-2.0 mg/kg prednisone per day **(failure defined as not having a response to at least a 3-month trial or is corticosteroid-dependent)**:

DRUG/DOSE: _____ Dates of therapy: _____

AND

- ❑ Therapy with Doptelet will be initiated at 10 to 20 mg once daily (depending on the member's age), unless otherwise indicated, **AND** the provider will adhere to established dosing level recommendations based on platelet count **[see dose table(s) in reauthorization section]**

Diagnosis: Chronic Immune Thrombocytopenia ONLY

Reauthorization: 6 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member's platelet count has not reached target level to recommend discontinuation of therapy

AND

- ❑ Document platelet count 2 weeks after therapy initiation: _____ **x10^9/L**

AND

(Continued on next page)

- ❑ Document current platelet count **[lab work measured within the date of this reauthorization request]**: _____ **x10^9/L**

AND

- ❑ Based on current platelet count, enter dose level (see tables below) at which therapy will continue: _____

TABLE 1: DOPTELET Tablets Recommended Dose Adjustments for Adult Patients with Chronic Immune Thrombocytopenia and Pediatric Patients 6 Years and Older with Persistent or Chronic Immune Thrombocytopenia

Platelet Count (x10^9/L)	Dose Adjustment or Action
Less than 50 after at least 2 weeks of DOPTELET	**Increase** One Dose Level (according to dose table below) [Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments]
Between 200 and 400	**Decrease** One Dose (according to dose table below) [Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments]
Greater than 400	**Stop DOPTELET**. [Increase platelet monitoring to twice weekly. When platelet count is less than 150 x10^9/L, decrease One Dose Level (according to dose table below) and reinitiate therapy.]
Less than 50 after 4 weeks of DOPTELET 40 mg once daily	**Discontinue DOPTELET.**
Greater than 400 after 2 weeks of DOPTELET 20 mg weekly	**Discontinue DOPTELET.**

TABLE 2: DOPTELET Tablet Dose Levels for Titration in Adult Patients with Chronic Immune Thrombocytopenia and Pediatric Patients 6 Years and Older with Persistent or Chronic Immune Thrombocytopenia

Dose	Dose Level
40 mg Once Daily	6
40 mg Three Times a Week **AND** 20 mg on the Four Remaining Days of Each Week	5
20 mg Once Daily (Initial Dose Regimen)	4
20 mg Three Times a Week	3
20 mg Twice a Week **OR** 40 mg Once Weekly	2
20 mg Once Weekly	1

(Continued on next page)

TABLE 3: DOPTELET SPRINKLE Dose Adjustments for Patients 1 Year to Less than 6 Years with Persistent or Chronic Immune Thrombocytopenia

Platelet Count (x10^9/L)	Dose Adjustment or Action
Less than 50 after at least 2 weeks of DOPTELET SPRINKLE	**Increase** One Dose Level (according to dose table below) [Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments]
Between 200 and 400	**Decrease** One Dose (according to dose table below) [Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments]
Greater than 400	**Stop DOPTELET SPRINKLE**. [Increase platelet monitoring to twice weekly. When platelet count is less than 150 x10^9/L, decrease One Dose Level (according to dose table below) and reinitiate therapy.]
Less than 50 after 4 weeks of DOPTELET SPRINKLE 20 mg once daily	**Discontinue DOPTELET SPRINKLE.**
Greater than 400 after 2 weeks of DOPTELET SPRINKLE 10 mg weekly	**Discontinue DOPTELET SPRINKLE.**

TABLE 4: DOPTELET SPRINKLE Dose Levels for Titration in Pediatric Patients 1 Year to Less than 6 Years with Persistent or Chronic Immune Thrombocytopenia

Dose	Dose Level
20 mg Once Daily	6
20 mg Three Times a Week **AND** 10 mg on the Four Remaining Days of Each Week	5
10 mg Once Daily (Initial Dose Regimen)	4
10 mg Three Times a Week	3
10 mg Twice a Week **OR** 20 mg Once Weekly	2
10 mg Once Weekly	1

Medication being provided by Specialty Pharmacy – Proprium Rx

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee**: 6/20/2019; **11/20/2025**
REVISED/UPDATED/REFORMATTED: 8/13/2019; 11/15/2019; 8/31/2020; 10/11/2021; 11/8/2021; 11/22/2021; 9/23/2025, **12/12/2025**